[go: up one dir, main page]

CN102920810A - A mucous membrane care product for Behcet's syndrome - Google Patents

A mucous membrane care product for Behcet's syndrome Download PDF

Info

Publication number
CN102920810A
CN102920810A CN2012104716276A CN201210471627A CN102920810A CN 102920810 A CN102920810 A CN 102920810A CN 2012104716276 A CN2012104716276 A CN 2012104716276A CN 201210471627 A CN201210471627 A CN 201210471627A CN 102920810 A CN102920810 A CN 102920810A
Authority
CN
China
Prior art keywords
parts
syndrome
behcet
radix
cat
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN2012104716276A
Other languages
Chinese (zh)
Other versions
CN102920810B (en
Inventor
汉仲月
汪秀芹
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to CN 201210471627 priority Critical patent/CN102920810B/en
Publication of CN102920810A publication Critical patent/CN102920810A/en
Application granted granted Critical
Publication of CN102920810B publication Critical patent/CN102920810B/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Landscapes

  • Medicines Containing Plant Substances (AREA)

Abstract

本发明公开了一种用于白塞氏综合征的粘膜护理物,属于妇科护理医疗领域,以解决白塞氏综合征的粘膜溃疡问题。其特征在于由多种中药加工而成,其原料配方和重量配比为:猫爪草6~10份,白药子8~15份,紫金牛8~15份,石龙芮6~10份,桃树胶6~10份,地龙8~15份,蜂蜡6~10份,萝藦8~15份,蛇含石3~6份。临床实验证明本发明用于白塞氏综合征具有疗效好和安全性较高的特点,值得临床应用、推广。The present invention discloses a mucosal care product for Behçet's syndrome, belonging to the field of gynecological nursing and medical treatment, and is used to solve the problem of mucosal ulcers in Behçet's syndrome. It is characterized by being processed from multiple traditional Chinese medicines, and its raw material formula and weight ratio are: 6-10 parts of cat's claw, 8-15 parts of white medicine seeds, 8-15 parts of Ardisia japonica, 6-10 parts of scutellaria baicalensis, 6-10 parts of peach gum, 8-15 parts of earthworms, 6-10 parts of beeswax, 8-15 parts of Radix Astragali, and 3-6 parts of serpent stone. Clinical experiments have shown that the present invention has the characteristics of good efficacy and high safety for Behçet's syndrome, and is worthy of clinical application and promotion.

Description

一种用于白塞氏综合征的粘膜护理物A mucous membrane care product for Behcet's syndrome

技术领域 technical field

本发明涉及妇科护理医疗领域,具体涉及一种用于白塞氏综合征的粘膜护理物。 The invention relates to the field of gynecological nursing and medical care, in particular to a mucosal care product for Behcet's syndrome.

背景技术 Background technique

白塞氏综合征(Behcet’s disease,BD)是一种全身性、慢性、血管炎性疾病。临床上以口腔溃疡、生殖器溃疡、眼炎及皮肤损害为突出表现,又称为口-眼-生殖器综合征(贝赫切特综合征)。该病常累及神经系统、消化道、肺、肾以及附睾等器官,病情呈反复发作和缓解的交替过程。该病由土耳其皮肤科医师Behcet首次报告,以后世界各地均有发现。本病在日本、朝鲜、中国、中近东(土耳其、伊朗)以及东地中海地区发病率远较西方欧美国家为高。该病发病年龄大多为16~40岁的青壮年,中国以女性略占多数。 Behcet's syndrome (Behcet's disease, BD) is a systemic, chronic, vasculitic disease. Clinically, oral ulcers, genital ulcers, ophthalmia and skin lesions are the prominent manifestations, also known as mouth-eye-genital syndrome (Behcet syndrome). The disease often involves the nervous system, digestive tract, lung, kidney, epididymis and other organs. The disease was first reported by Behcet, a Turkish dermatologist, and has since been found all over the world. The incidence of this disease in Japan, North Korea, China, the Middle East (Turkey, Iran) and the Eastern Mediterranean is far higher than that in Western European and American countries. The age of onset of the disease is mostly young adults aged 16 to 40, and women account for a slight majority in China.

该病发病病因不明确,感染、遗传、免疫异常都有证明与本病发病相关。病变以侵蚀小动脉、小静脉及微血管为主,病损的血管和周围组织中可见到淋巴细胞和单核细胞浸润、血管壁坏死、扩张、破裂,腔内血栓形成或纤维增生造成管腔狭窄,病变可累及全身血管,如皮肤黏膜、眼睛以及全身多系统的细小血管炎,多数病例还伴有不同成度的关节症状。 The etiology of the disease is not clear, and infection, heredity, and immune abnormalities have been proved to be related to the disease. Lesions mainly erode arterioles, venules, and microvessels. Infiltration of lymphocytes and monocytes, necrosis, expansion, and rupture of vessel walls can be seen in lesioned vessels and surrounding tissues, and intraluminal thrombosis or fibrous hyperplasia causes luminal stenosis , the pathological changes can involve systemic blood vessels, such as skin mucous membranes, eyes, and small vasculitis of multiple systems throughout the body, and most cases are also accompanied by joint symptoms of varying degrees.

口腔和生殖器溃疡是BD首发症状,98%以上的患者可见口腔溃疡,80%的患者可见生殖器溃疡。溃疡表现为颊黏膜、舌缘、唇、软腭以及生殖器等处可见到红色小结,继以溃疡形成,溃疡直径一般为2~3mm。有的以疱疹起病,约l4天左右消退,口腔溃疡不留疤痕,但是生殖器溃疡可因反复发作或者持续数周不愈最后遗有疤痕者。在活动期,复发性口腔溃疡每年发作至少3次,溃疡此起彼伏。而女性生殖器溃疡主要见于大、小阴唇,其次为阴道,在也可以出现在会阴或肛门周围,疼痛症状比较明显。 Mouth and genital ulcers are the first symptoms of BD. More than 98% of patients can see oral ulcers, and 80% of patients can see genital ulcers. Ulcers manifest as red nodules on the buccal mucosa, edge of the tongue, lips, soft palate, and genitals, followed by ulceration, and the diameter of the ulcer is generally 2 to 3 mm. Some have herpes onset, subsided in about 14 days, and oral ulcers do not leave scars, but genital ulcers may be left with scars due to repeated attacks or persistent unhealed for several weeks. In the active stage, recurrent oral ulcers show up at least 3 times a year, and ulcers come and go. The female genital ulcers are mainly seen in the labia majora and minora, followed by the vagina, and can also appear around the perineum or anus, and the pain symptoms are more obvious.

该病的治疗目前主要为非甾体抗炎药、糖皮质激素,甚至使用免疫抑制剂,如秋水仙碱或者环磷酰胺。对于粘膜溃疡,口腔溃疡一般使用龙胆紫,阴部溃疡一般使用0.1%醋酸氟羟泼尼松软膏或者四环素软膏,如果溃疡比较严重则就需要口服沙利度胺(反应停)。但是以上药物使用,仅仅是针对溃疡伴发的感染,并不能解决溃疡面疼痛的问题,且使用激素类粘膜护理物容易引发皮肤快速硬化、色素沉积等弊端。 The treatment of this disease is currently mainly based on non-steroidal anti-inflammatory drugs, glucocorticoids, and even the use of immunosuppressants such as colchicine or cyclophosphamide. For mucosal ulcers, gentian violet is generally used for oral ulcers, and 0.1% fludrysone acetate ointment or tetracycline ointment is generally used for genital ulcers. If the ulcers are serious, thalidomide (thalidomide) should be taken orally. However, the use of the above drugs is only for the infection associated with the ulcer, and cannot solve the problem of pain on the ulcer surface, and the use of hormone-based mucosal care products is likely to cause disadvantages such as rapid skin hardening and pigmentation.

故而,目前临床上尚缺乏一种可以缓解白塞氏综合征粘膜溃疡疼痛、促进溃疡面愈合的粘膜护理物。 Therefore, there is still a lack of a mucosal care product that can relieve the pain of Behcet's syndrome mucosal ulcer and promote the healing of the ulcer.

发明内容 Contents of the invention

本发明的技术任务是针对以上现有技术的不足,提供一种疗效肯定,且副作用比较少的用于白塞氏综合征的粘膜护理物。 The technical task of the present invention is to provide a mucous membrane care product for Behcet's syndrome with positive curative effect and relatively few side effects against the above deficiencies in the prior art.

本发明解决其技术问题的技术方案是:一种用于白塞氏综合征的粘膜护理物,其特征在于由多种中药加工而成,其原料配方和重量配比为:猫爪草6~10份,白药子8~15份,紫金牛8~15份,石龙芮6~10份,桃树胶6~10份,地龙8~15份,蜂蜡6~10份,萝藦8~15份,蛇含石3~6份。 The technical scheme for solving the technical problems of the present invention is: a mucous membrane care product for Behcet's syndrome, which is characterized in that it is processed from a variety of traditional Chinese medicines, and its raw material formula and weight ratio are: Cat's Claw 6~ 10 parts, 8~15 parts of Baiyaozi, 8~15 parts of Zijinniu, 6~10 parts of Shilongrui, 6~10 parts of peach gum, 8~15 parts of earthworm, 6~10 parts of beeswax, 8~15 parts of radish parts, snake contains 3~6 parts of stone.

其最佳重量配比为:猫爪草8份,白药子10份,紫金牛10份,石龙芮8份,桃树胶8份,地龙10份,蜂蜡8份,萝藦10份,蛇含石5份。 The optimal weight ratio is: 8 parts of cat's claw grass, 10 parts of Baiyaozi, 10 parts of Zijinniu, 8 parts of Shilongrui, 8 parts of peach gum, 10 parts of earthworm, 8 parts of beeswax, 10 parts of radish, snake Contains 5 parts of stone.

优化方案为,在上述基础上加用猫眼草3份。 The optimization scheme is to add 3 parts of cat's eye grass on the basis of the above.

其中所述的:猫爪草,为毛茛科植物小毛茛Ranunculus ternatus Thunb. 的干燥块根。性味甘、辛,温。归肝、肺经。功可散结,消肿。 Wherein said: cat's claw grass, is the dry tuberous root of Ranunculus ternatus Thunb. of Ranunculaceae plant. Nature and flavor are sweet, pungent, warm. Return liver, lung meridian. Function can dissipate stagnation and detumescence.

白药子,为防己科千金藤属植物头花千金藤Stephania cepharantha Hayata,以块根入药。性味苦,寒。功可清热解毒,凉血止血,散瘀消肿。 Baiyaozi is Stephania cephalantha Hayata, the head flower of Stephania cephalantha Hayata, which is used as medicine with tubers. Nature and flavor are bitter, cold. Function can clear heat and detoxify, cool blood to stop bleeding, dissipate blood stasis and reduce swelling.

紫金牛,为紫金牛科紫金牛属植物紫金牛Ardisia japonica (Hornsted) Blume,以全株入药。性味辛,平。功可止咳化痰,祛风解毒,活血止痛。 Zijinniu is Ardisia japonica (Hornsted) Blume, a plant of the genus Zijinniu in the family Zijinbu. It is used as medicine with the whole plant. Nature and flavor are pungent, flat. The function can relieve cough and reduce phlegm, dispel wind and detoxify, promote blood circulation and relieve pain.

石龙芮,为毛茛科毛茛属植物石龙芮Ranunculus sceleratus L.,以全草入药。性味苦、辛,平。有毒。功可消肿,拔毒散结,截疟。 Shi Longrui, Ranunculus sceleratus L., is a plant of Ranunculaceae Ranunculus genus Ranunculus sceleratus L., the whole herb is used as medicine. Nature and flavor are bitter, pungent, flat. poisonous. The function can reduce swelling, expel toxins and dissipate stagnation, and cut malaria.

桃树胶,为蔷薇科植物桃Prunus persica (L.)Batsch,树干上流出的树脂。性味苦、平。功可活血,益气,止渴。 Peach gum is the resin that flows from the trunk of Prunus persica (L.) Batsch, a plant in the Rosaceae family. Nature and flavor are bitter, flat. Gong can activate blood, replenish qi, and quench thirst.

地龙,为巨蚓科动物参环毛蚓Pheretima aspergillum (E. Perrier)、通俗环毛蚓Pheretima vulgaris Chen、威廉环毛蚓Pheretima guillelmi (Michaelsen)或栉盲环毛蚓Pheretima pectinifera Michaelsen的干燥体,性味苦、平,功可清热,平肝,止喘,通络。 Earth Dragon, is the dried body of Pheretima aspergillum (E. Perrier), Pheretima vulgaris Chen, Pheretima guillelmi (Michaelsen) or Pheretima pectinifera Michaelsen, Nature and flavor are bitter, flat, and its functions can clear away heat, calm the liver, relieve asthma, and dredge collaterals.

蜂蜡,为蜜蜂科昆虫中华蜜蜂Apis cerana Fabricius或意大利蜂Apis mellifera Linnaeus分泌的蜡。性味甘,微温。功可收涩,敛疮,生肌,止痛。 Beeswax is the wax secreted by Apis cerana Fabricius or Italian bee Apis mellifera Linnaeus. Nature and flavor are sweet, tepor. Gong can be astringent, suppress sores, promote granulation, and relieve pain.

萝藦,为萝藦科萝藦属植物萝藦Metaplexis japonica (Thunb.)Makino,以块根、全草入药。性味甘、微辛,温。功可补气益精,行气活血,消肿解毒。 Radix radix, is Radix Radix Metaplexis japonica (Thunb.) Makino, a plant of the genus Radix Radix genus Radix, which is used as medicine with tubers and whole plants. Nature and flavor are sweet, slightly pungent, warm. Gong can invigorate qi and benefit essence, promote qi and blood circulation, reduce swelling and detoxify.

蛇含石,为氧化物矿物褐铁矿Pyrite;Limonite的结核。性味甘;寒。归心包;肝经。功可安神镇惊;止血定痛。 Snake contains stone, which is the nodules of the oxide mineral limonite Pyrite; Limonite. Sweet in nature and flavor; cold. GUI Xinbao; Liver Channel. The function can soothe the nerves and calm convulsions; stop bleeding and relieve pain.

猫眼草,为大戟科大戟属植物猫眼草Euphorbia lunulata Bunge的全草。性味苦,凉。功可利尿消肿,拔毒止痒。 Cat's-eye grass is the whole plant of Euphorbia lunulata Bunge, a plant of Euphorbia genus Euphorbia. Nature and flavor are bitter, cool. Function can promote diuresis, detumescence, detoxify and relieve itching.

组方原理:白塞氏综合征是一种全身性、慢性、血管炎性疾病。该病发病病因不明确,可能与感染、遗传、环境以及免疫功能异常等因素有关。病变以侵蚀小动脉、小静脉及微血管为主,病损的血管和周围组织中可见到淋巴细胞和单核细胞浸润、血管壁坏死、扩张、破裂,腔内血栓形成或纤维增生造成管腔狭窄,病变可累及全身血管,如皮肤黏膜、眼睛以及全身多系统的细小血管炎,多数病例还伴有不同成度的关节症状。中医治疗往往从清热、除湿入手,但是发明人多年临床经验认为,本病属于内因外因合而致病,流毒于全身。 Prescription principle: Behcet's syndrome is a systemic, chronic, vascular inflammatory disease. The etiology of the disease is not clear, and it may be related to factors such as infection, heredity, environment, and abnormal immune function. Lesions mainly erode arterioles, venules, and microvessels. Infiltration of lymphocytes and monocytes, necrosis, expansion, and rupture of vessel walls can be seen in lesioned vessels and surrounding tissues, and intraluminal thrombosis or fibrous hyperplasia causes luminal stenosis , the pathological changes can involve systemic blood vessels, such as skin mucous membranes, eyes, and small vasculitis of multiple systems throughout the body, and most cases are also accompanied by joint symptoms of varying degrees. Traditional Chinese medicine treatment often starts with heat-clearing and dehumidification, but the inventor's many years of clinical experience believes that this disease belongs to the combination of internal and external causes, and the toxin spreads throughout the body.

本发明与现有技术比较,具有以下特点: Compared with the prior art, the present invention has the following characteristics:

1、组方独特:取猫爪草散结、白药子清热解毒、紫金牛祛风解毒,三者合作,分别针对邪风、热毒入手,解决局部血管壁坏死而致粘膜溃疡,经过发明人多年临床摸索得出,这三味药配合可以有效的解决溃疡的事发原因——细小血管炎,即致病必求其本; 1. The formula is unique: take Cat's Claw to Sanjie, Baiyaozi to clear away heat and detoxify, and Zijinniu to dispel wind and detoxify. The three cooperate to start with evil wind and heat toxin respectively, and solve the mucosal ulcer caused by local vascular wall necrosis. After the inventor After many years of clinical exploration, it has been found that the combination of these three herbs can effectively solve the cause of the ulcer - small vasculitis, that is, the cause of the disease must seek its root;

2、标本兼顾:猫爪草、白药子、紫金牛为治本之药,而粘膜溃疡带来的疼痛,则通过紫金牛活血止痛、蜂蜡敛疮生肌止痛、蛇含石止血定痛,急性期疼痛甚,则优化方案中加入猫眼草拔毒止痒,多种角度入手,达到迅速止痛的效果,该种止痛药物的组合是发明人多年试验所得,对粘膜溃疡具有特异性; 2. Taking into account both specimens: cat's claw grass, baiyaozi, and Zijinniu are the medicines for the root cause, and the pain caused by mucosal ulcers can be cured by Zijinniu promoting blood circulation and relieving pain, beeswax astringing sores, promoting granulation and relieving pain, and snake containing stones to stop bleeding and relieve pain. If the pain is severe, cat’s eye grass is added to the optimized plan to remove poison and relieve itching, and start from multiple angles to achieve the effect of rapid pain relief. This combination of painkillers is obtained by the inventor for many years, and it is specific to mucosal ulcers;

3、粘膜修复效果迅速:猫爪草、石龙芮、地龙三药水煎剂的体外试验证实可以促进粘膜修复能力,且该种粘膜修复能力并不是通过扩张血管、增加局部血供途径完成的,而是通过增加新生毛细血管管壁细胞细胞膜稳定性而产生的作用,也即使得新生血管不再受到淋巴细胞和单核细胞浸润而产生病理影响; 3. The effect of mucosal repair is rapid: the in vitro test of the decoction of cat's claw grass, Shilongrui and Dilong three medicines has proved that it can promote the ability of mucosal repair, and this kind of mucosal repair ability is not completed by dilating blood vessels and increasing local blood supply. , but by increasing the stability of the cell membrane of the new capillary wall cells, that is, the new blood vessels are no longer infiltrated by lymphocytes and monocytes and have pathological effects;

4、使用地龙这一通络药物,使得药物局部扩散速率增加,且局部无刺激性; 4. The use of earthworm, a meridian dredging drug, increases the local diffusion rate of the drug, and the local area is non-irritating;

5、桃树胶、蜂蜡可以在粘膜表面形成保护膜,使得阴道粘膜溃疡面不容易受到污染而产生继发感染,从而加入愈合; 5. Peach gum and beeswax can form a protective film on the surface of the mucous membrane, making the ulcer surface of the vaginal mucous membrane less prone to contamination and secondary infection, thus contributing to healing;

6、BD属于本虚标实,故局部选用桃树胶益气、萝藦补气益精,此二药外用局部吸收效果好,优于黄芪、党参、沙参等补益药物; 6. BD belongs to deficiency in origin and excess in superficiality, so peach tree gum is used locally to replenish qi and radish to invigorate qi and essence. The local absorption effect of these two medicines is better than that of astragalus, codonopsis pilosula, and sand ginseng;

7、注重局部离子平衡:蛇含石成分为含水的三氧化二铁,以及锰、磷、钙、钒等多种微量元素,发明人研究结果显示,在处方中加入本药,有利于促进粘膜修复,可能由于BD发病,局部的离子失衡有关; 7. Pay attention to local ion balance: the composition of snake stones is ferric oxide containing water, and various trace elements such as manganese, phosphorus, calcium, vanadium, etc. The research results of the inventors show that adding this medicine in the prescription is beneficial to promote mucous membrane Repair, it may be related to local ion imbalance due to the onset of BD;

8、避免使用清湿热、化湿药物,因为清热化湿药物多具有燥性,短期效果良好,但是长期预后不好,复发率高; 8. Avoid the use of heat-clearing and damp-removing drugs, because most of the heat-clearing and damp-removing drugs are dry, and the short-term effect is good, but the long-term prognosis is poor and the recurrence rate is high;

9、避免使用具有扩张血管作用的药物,其原因在于扩张血管亦会导致毛细血管管壁通透性增加,BD病理基础本身就有血管壁坏死、扩张、破裂,继而腔内血栓形成或纤维增生造成管腔狭窄,扩张血管可以暂时的缓解管腔狭窄,但是反而加重了血管壁负担; 9. Avoid the use of drugs that have the effect of dilating blood vessels. The reason is that dilating blood vessels will also lead to increased permeability of capillary walls. The pathological basis of BD itself is necrosis, expansion, and rupture of blood vessel walls, followed by intraluminal thrombosis or fibrous hyperplasia. Causes luminal stenosis, dilating blood vessels can temporarily relieve luminal stenosis, but instead increases the burden on the vascular wall;

10、本发明粘膜护理物原料用量是经发明人进行大量摸索总结得出的,各原料用量为在下述重量份范围都具有较好的疗效。 10. The dosage of the raw materials of the mucous membrane care product of the present invention is obtained through a lot of exploration by the inventor, and the dosage of each raw material has a good curative effect in the following parts by weight.

具体实施方式 Detailed ways

以下结合实际情况,对本发明的具体实施方式作详细说明。 The specific implementation manner of the present invention will be described in detail below in combination with the actual situation.

实施例1,原料药重量配比:猫爪草6g,白药子8g,紫金牛8g,石龙芮6g,桃树胶6g,地龙8g,蜂蜡6g,萝藦8g,蛇含石3g。 Example 1, the weight ratio of raw materials: Cat's claw grass 6g, Baiyaozi 8g, Zijinniu 8g, Shilongrui 6g, peach gum 6g, earthworm 8g, beeswax 6g, radish 8g, snake containing stone 3g.

实施例2,原料药重量配比:猫爪草10g,白药子15g,紫金牛15g,石龙芮10g,桃树胶10g,地龙15g,蜂蜡10g,萝藦15g,蛇含石6g。 Example 2, the weight ratio of raw materials: cat's claw grass 10g, Baiyaozi 15g, Zijinniu 15g, Shilongrui 10g, peach gum 10g, earthworm 15g, beeswax 10g, radish 15g, snake containing stone 6g.

实施例3,原料药重量配比:猫爪草8g,白药子10g,紫金牛10g,石龙芮8g,桃树胶8g,地龙10g,蜂蜡8g,萝藦10g,蛇含石5g。 Example 3, the weight ratio of raw materials: cat's claw grass 8g, Baiyaozi 10g, Zijinniu 10g, Shilongrui 8g, peach gum 8g, earthworm 10g, beeswax 8g, radish 10g, snake containing stone 5g.

实施例1~3使用时,将本发明中药猫爪草、白药子、紫金牛、石龙芮、地龙、蛇含石和萝藦加水煎煮两次,合并滤液,加热状态下加入桃树胶、蜂蜡,浓缩后,分早晚阴道粘膜局部涂用。 When using Examples 1 to 3, add water to decoct the Chinese medicine Cat's Claw Grass, Baiyaozi, Zijinniu, Shilongrui, Earthworm, Shehanshi and Radix Radix for two times, combine the filtrate, add peach gum, Beeswax, after concentrated, is applied locally on the vaginal mucosa in the morning and evening.

实施例4,原料药重量配比:猫爪草6g,白药子8g,紫金牛8g,石龙芮6g,桃树胶6g,地龙8g,蜂蜡6g,萝藦8g,蛇含石3g,猫眼草2g。 Example 4, the weight ratio of raw materials: cat's claw grass 6g, Baiyaozi 8g, Zijinniu 8g, Shilongrui 6g, peach gum 6g, earthworm 8g, beeswax 6g, radish 8g, snake containing stone 3g, cat's eye grass 2g.

实施例5,原料药重量配比:猫爪草10g,白药子15g,紫金牛15g,石龙芮10g,桃树胶10g,地龙15g,蜂蜡10g,萝藦15g,蛇含石6g,猫眼草2g。 Example 5, the weight ratio of raw materials: cat's claw grass 10g, Baiyaozi 15g, Zijinniu 15g, Shilongrui 10g, peach gum 10g, earthworm 15g, beeswax 10g, radish 15g, snake containing stone 6g, cat's eye grass 2g.

实施例6,原料药重量配比:猫爪草8g,白药子10g,紫金牛10g,石龙芮8g,桃树胶8g,地龙10g,蜂蜡8g,萝藦10g,蛇含石5g,猫眼草2g。 Example 6, the weight ratio of raw materials: cat's claw grass 8g, Baiyaozi 10g, Zijinniu 10g, Shilongrui 8g, peach gum 8g, earthworm 10g, beeswax 8g, radish 10g, snake containing stone 5g, cat's eye grass 2g.

实施例4~6使用时,将本发明中药猫爪草、白药子、紫金牛、石龙芮、地龙、蛇含石、萝藦和猫眼草加水煎煮两次,合并滤液,加热状态下加入桃树胶、蜂蜡,浓缩后,分早晚阴道粘膜局部涂用。 When embodiment 4~6 is used, Chinese medicine cat's claw of the present invention, Baiyaozi, Zijinniu, Shilongrui, Dilong, Shehanshi, radish and cat's eye grass are decocted twice, and the combined filtrate is heated. Add peach gum and beeswax, concentrate, apply to vaginal mucosa in the morning and evening.

以上实施例除上述制备方法外,可以结合现有药剂学方法制成油膏、乳膏,局部使用。 In addition to the above preparation methods, the above embodiments can be combined with existing pharmaceutical methods to make ointments and creams for local use.

上述粘膜护理物的有效组合,互相协调,可以有效达到缓解白塞氏综合征粘膜溃疡疼痛之目的,促进溃疡愈合,且副作用较少。上述结果为临床资料充分证明,有关资料如下,其中研究粘膜护理物使用为实施例3和实施例6中的原料药重量配比。 The effective combination and mutual coordination of the above-mentioned mucosal care products can effectively relieve the pain of Behcet's syndrome mucosal ulcer, promote ulcer healing, and have fewer side effects. The above results are fully proved by the clinical data, and the relevant data are as follows, wherein the weight ratio of the bulk drug in Example 3 and Example 6 is used for the research on mucosal care.

1 对象与方法。 1 Objects and methods.

1.1 对象。 1.1 Subject.

1.1.1 纳入标准:为2009年1月~2012年9月确诊白塞氏综合征伴有复发性生殖器溃疡女性患者,所述的复发性指的是一年内至少反复发作3次。各病例均营养状况好,血糖、血脂及肝肾功能均在正常范围。 1.1.1 Inclusion criteria: female patients with Behcet's syndrome and recurrent genital ulcer diagnosed between January 2009 and September 2012, the recurrent refers to at least 3 repeated attacks within one year. The nutritional status of each case was good, and the blood sugar, blood fat, liver and kidney functions were all within the normal range.

1.1.2 白塞氏综合征诊断依据:反复性口腔溃疡(包括轻型小溃疡、较重型大溃疡或疱疹样型溃疡),并有下述4项中的任何2项相继或同时出现者:①复发性生殖器溃疡或疤痕:必须经医师观察到或由患者本人提供并被确认为是可靠的;②眼损害:包括前葡萄膜炎和后葡萄膜炎,裂隙灯检查时发现玻璃体浑浊或视网膜血管炎;③皮肤损害:包括结节性红斑、假性毛囊炎及脓性丘疹,未用过糖皮质激素、非青春期者而出现的痤疮样结节;④针刺反应阳性:试验后经24~48小时后由医师判定的阳性反应。 1.1.2 Diagnosis basis of Behcet’s syndrome: recurrent oral ulcers (including mild small ulcers, relatively heavy large ulcers or herpetic ulcers), and any two of the following four items occur sequentially or simultaneously: ① Recurrent genital ulcers or scars: must be observed by a physician or provided by the patient himself and confirmed to be reliable; ②Eye damage: including anterior uveitis and posterior uveitis, vitreous opacity or retinal blood vessels found during slit lamp examination ③Skin lesions: including erythema nodosum, pseudofolliculitis and purulent papules, acne-like nodules in non-adolescents who have not used glucocorticoids; Positive reaction judged by physician after 48 hours.

1.1.3病例情况:入选60例,年龄跨度16~41岁,平均年龄28.13±9.62岁。 1.1.3 Cases: 60 cases were selected, ranging in age from 16 to 41 years, with an average age of 28.13±9.62 years.

1.2 方法。 1.2 Method.

1.2.1分组:入选60例,分为对照组30例,治疗组30例。两组病例年龄差异无统计学意义,P>0.05,具有可比性。 1.2.1 Grouping: 60 cases were selected and divided into 30 cases in the control group and 30 cases in the treatment group. There was no significant difference in age between the two groups, P>0.05, which was comparable.

1.2.2研究方法:对照组局部外用0.1%醋酸氟羟泼尼松软膏,治疗组采用本发明实施例3中的药物外用,急性期疼痛比较重的采用实施例6中所得药物外用。所有病例用药均为2次/d,共用10d。 1.2.2 Research method: the control group used 0.1% fludrylprednisolone acetate ointment locally, the treatment group used the drug in Example 3 of the present invention for external use, and those with severe pain in the acute phase used the drug obtained in Example 6 for external use. All cases were administered twice a day for 10 days.

1.2.3 安全性评价:用药前后均进行血、尿、粪常规,肝、肾功能、心电图等监测。 1.2.3 Safety evaluation: Blood, urine and feces routine, liver and kidney function, and electrocardiogram were monitored before and after the drug.

1.2.4 统计学分析:用SPSS 13.0进行统计分析,P<0.05表示有显著性意义。 1.2.4 Statistical analysis: SPSS 13.0 was used for statistical analysis, and P<0.05 indicated significant significance.

2 结果。 2 results.

2.1两组疗效对照:疼痛明显减轻或缓解。治疗10天后治疗组的治愈率(33. 3%)、显效率(60. 0%)均明显高于对照组的治愈率(10. 0%)、显效率(10. 0%),差异具有统计学意义(p<0.05)。 2.1 Comparison of curative effects between the two groups: the pain was significantly reduced or relieved. After 10 days of treatment, the cure rate (33.3%) and markedly effective rate (60.0%) of the treatment group were significantly higher than those of the control group (10.0%) and markedly effective rate (10.0%). Statistically significant (p<0.05).

2.2两组有效病例疼痛缓解时间:有效病例中,治疗组平均疼痛缓解时间为4.11±1.08d,对照组为7.32±3.17d,二者比较,治疗组明显优于对照组(p<0.01)。 2.2 Pain relief time of the effective cases in the two groups: Among the effective cases, the average pain relief time of the treatment group was 4.11±1.08d, and that of the control group was 7.32±3.17d. Compared with the two groups, the treatment group was significantly better than the control group (p<0.01).

2.3不良反应:两组均未出现明显不良反应记录。 2.3 Adverse reactions: No obvious adverse reactions were recorded in the two groups.

2.4复发率:追踪病例1年,1年内治疗组有30.00%(9/30)复发,对照组有63.33%(19/30)复发,二者比较,治疗组复发率明显低于对照组(p<0.01)。 2.4 Recurrence rate: Follow up the cases for 1 year, within 1 year, 30.00% (9/30) of the treatment group relapsed, and 63.33% (19/30) of the control group relapsed. Comparing the two, the recurrence rate of the treatment group was significantly lower than that of the control group (p <0.01).

3.结论。 3. in conclusion.

本研究结果提示,本发明用于白塞氏综合征具有疗效好和安全性较高的特点,值得临床应用、推广。 The results of this study suggest that the present invention has the characteristics of good curative effect and high safety when used for Behcet's syndrome, and is worthy of clinical application and promotion.

Claims (3)

1. mucomembranous nursing thing that is used for Behcet's syndrome, it is characterized in that being processed by plurality of Chinese, its composition of raw materials and weight proportion are: 6 ~ 10 parts of Radix Ranunculi Ternatis, 8 ~ 15 parts of Radix Stephaniae Cepharanthaes, 8 ~ 15 parts of Herba Ardisiae Japonicaes, 6 ~ 10 parts of Herba Ranunculi Scelerati (Radix Anemones rupicolae)s, 6 ~ 10 parts of gumshiraz, 8 ~ 15 parts of Pheretimas, 6 ~ 10 parts in Cera Flava, 8 ~ 15 parts of Herba seu radix metaplexis, 3 ~ 6 parts of Limonitums.
2. a kind of mucomembranous nursing thing for Behcet's syndrome according to claim 1 is characterized in that its weight proportion is: 8 parts of Radix Ranunculi Ternatis, 10 parts of Radix Stephaniae Cepharanthaes, 10 parts of Herba Ardisiae Japonicaes, 8 parts of Herba Ranunculi Scelerati (Radix Anemones rupicolae)s, 8 parts of gumshiraz, 10 parts of Pheretimas, 8 parts in Cera Flava, 10 parts of Herba seu radix metaplexis, 5 parts of Limonitums.
3. a kind of mucomembranous nursing thing for Behcet's syndrome according to claim 1 is characterized in that: comprise that also weight proportion is 3 parts Herba euphorbiae lunulatae.
CN 201210471627 2012-11-20 2012-11-20 A mucous membrane care product for Behcet's syndrome Expired - Fee Related CN102920810B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN 201210471627 CN102920810B (en) 2012-11-20 2012-11-20 A mucous membrane care product for Behcet's syndrome

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN 201210471627 CN102920810B (en) 2012-11-20 2012-11-20 A mucous membrane care product for Behcet's syndrome

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201310394963.XA Division CN103479756B (en) 2012-11-20 2012-11-20 Mucosa nursing matter for Behcet's syndromes

Publications (2)

Publication Number Publication Date
CN102920810A true CN102920810A (en) 2013-02-13
CN102920810B CN102920810B (en) 2013-10-02

Family

ID=47635835

Family Applications (1)

Application Number Title Priority Date Filing Date
CN 201210471627 Expired - Fee Related CN102920810B (en) 2012-11-20 2012-11-20 A mucous membrane care product for Behcet's syndrome

Country Status (1)

Country Link
CN (1) CN102920810B (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103316270A (en) * 2013-07-01 2013-09-25 丁霄雁 Preparation method of powder of medicine for treating postnatal perineum mucosal lesion

Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0606786A2 (en) * 1993-01-15 1994-07-20 Rongxiang Xu A pharmaceutical composition for treating thermal injuries of warm blooded mammals and human
JPH11171784A (en) * 1997-12-09 1999-06-29 Noevir Co Ltd External preparation for skin
CN1364538A (en) * 2001-01-11 2002-08-21 杨孟君 Nano bronchitis treating medicine and its preparing method
WO2002080951A1 (en) * 2001-04-06 2002-10-17 Synergistix Biotech, Inc. Herbal extracts for the treatment of cancer
JP2003095912A (en) * 2001-09-20 2003-04-03 Noevir Co Ltd Skin care preparation
JP2003335619A (en) * 2002-05-14 2003-11-25 Noevir Co Ltd Skin care preparation for external use
CN1606995A (en) * 2003-10-16 2005-04-20 王伟良 Traditional Chinese medicine preparation for treating uremia and its preparation method
CN1895343A (en) * 2006-06-10 2007-01-17 江国潮 Externally-applied ointment for treating chronic scrotum eczema and its preparation
US20090041680A1 (en) * 2007-08-07 2009-02-12 Foamix Ltd. Wax Foamable Vehicle and Pharmaceutical Compositions Thereof
CN101810761A (en) * 2010-04-29 2010-08-25 李三猛 Medicament for treating tuberculosis

Patent Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0606786A2 (en) * 1993-01-15 1994-07-20 Rongxiang Xu A pharmaceutical composition for treating thermal injuries of warm blooded mammals and human
JPH11171784A (en) * 1997-12-09 1999-06-29 Noevir Co Ltd External preparation for skin
CN1364538A (en) * 2001-01-11 2002-08-21 杨孟君 Nano bronchitis treating medicine and its preparing method
WO2002080951A1 (en) * 2001-04-06 2002-10-17 Synergistix Biotech, Inc. Herbal extracts for the treatment of cancer
JP2003095912A (en) * 2001-09-20 2003-04-03 Noevir Co Ltd Skin care preparation
JP2003335619A (en) * 2002-05-14 2003-11-25 Noevir Co Ltd Skin care preparation for external use
CN1606995A (en) * 2003-10-16 2005-04-20 王伟良 Traditional Chinese medicine preparation for treating uremia and its preparation method
CN1895343A (en) * 2006-06-10 2007-01-17 江国潮 Externally-applied ointment for treating chronic scrotum eczema and its preparation
US20090041680A1 (en) * 2007-08-07 2009-02-12 Foamix Ltd. Wax Foamable Vehicle and Pharmaceutical Compositions Thereof
CN101810761A (en) * 2010-04-29 2010-08-25 李三猛 Medicament for treating tuberculosis

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
陈爱林等: "痹证1号配合西药治疗白塞氏病38 例", 《陕西中医》, vol. 30, no. 12, 31 December 2009 (2009-12-31), pages 1617 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103316270A (en) * 2013-07-01 2013-09-25 丁霄雁 Preparation method of powder of medicine for treating postnatal perineum mucosal lesion
CN103316270B (en) * 2013-07-01 2015-03-18 丁霄雁 Preparation method of powder of medicine for treating postnatal perineum mucosal lesion

Also Published As

Publication number Publication date
CN102920810B (en) 2013-10-02

Similar Documents

Publication Publication Date Title
CN103071138B (en) Chinese medicinal composition for treating chronic gastritis as well as preparation method and application
CN103751579A (en) Pharmaceutical composition for treating oral mucositis caused by radiotherapy for nasopharyngeal carcinoma and preparation method of pharmaceutical composition
CN102920810B (en) A mucous membrane care product for Behcet&#39;s syndrome
US20080317879A1 (en) Herb Composition for Asthma Maintenance Therapy and Manufacturing Method Thereof
CN100384463C (en) A medicine for treating uterine bleeding, hematemesis and hematochezia
CN103479756B (en) Mucosa nursing matter for Behcet&#39;s syndromes
CN101279024A (en) Chinese medicinal composition for treating anal fistula and method of preparing the same
CN113768978B (en) Yi medicine composition for treating ulcerative colitis and preparation method thereof
CN103479824B (en) A kind ofly treat Chinese medicine composition of chronic periodontitis and gastritis and preparation method thereof
CN104127585A (en) Mouth wash for treating oral ulcers and preparation method thereof
CN103751645B (en) Pharmaceutical composition for treating allergic rhinitis in children and preparation method thereof
CN102772670A (en) Traditional Chinese medicine composition for treating superficial gastritis
CN103656090B (en) A kind of enema solution for treating ulcerative colitis and its application
CN103690640B (en) A traditional Chinese medicine composition for treating enteric fever type hemorrhoids
CN102125618A (en) Medicine for treating lung meridian wind-heat type acne
CN113925952A (en) Application of traditional Chinese medicine composition in preparation of medicine for preventing and treating digestive tract tumor
CN119792436B (en) A traditional Chinese medicine preparation for treating ulcerative colitis and its preparation method
CN118490748B (en) A pharmaceutical composition for treating chronic non-atrophic gastritis caused by Hp, its preparation and application
CN118436739B (en) Traditional Chinese medicine composition for treating ulcerative colitis
CN103479915B (en) Traditional Chinese medicine composition for treating acute nephritis and preparation method thereof
CN100333773C (en) Gastric blood paste suppressing agent and its preparation method
CN102872342A (en) Chinese medicinal composition for treating gastric ulcer
CN109663020A (en) A kind of Yao medicinal composition that treating pruritus and its application
CN101637527A (en) Application method of amur cork for preparing digestive ulcer medicament
WO2019015102A1 (en) Traditional chinese medicine for treating acute pancreatitis

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20131002

Termination date: 20141120

EXPY Termination of patent right or utility model